1/20/2012

Orion Corporation: Annual Summary of Stock Exchange Releases published in 2011

ORION CORPORATION  STOCK EXCHANGE RELEASE 20 JAN 2012 AT 9.30 EET              

In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases published by the company in 2011. The releases are available on the internet website of Orion Corporation, at http://www.orion.fi/sereleases.
Orion points out that part of the information in the releases can have become out-dated.

Stock Exchange Releases in 2011

January
Jan 14th 201179,866 Orion A-shares converted into B-shares
Jan 19th 2011Annual Summary of Stock Exchange Releases published in 2010
Jan 20th 2011Orion invites analysts and media to Financial Statement Release conference on Wednesday 9 February 2011
Jan 24th 2011Orion sues Mylan in the U.S. to enforce its U.S. patent covering the proprietary drug Comtan®
Jan 31st 2011Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2011 AGM of Orion Corporation
February
Feb 9th 2011Orion Group Financial Statement Release for 2010
Feb 9th 2011Notice to the Annual General Meeting of Orion Corporation
March
Mar 1st 2011Orion Corporation: Transfer of 102,900 own B-shares
Mar 9th 2011Orion Group Annual Report 2010 published
Mar 31st 2011President and CEO Timo Lappalainen today at Annual General Meeting of Orion Corporation: Orion's sales developed well in early 2011
Mar 31st 2011Orion Corporation: Decisions by the AGM on 31 March 2011
Mar 31st 2011Orion Corporation: Organising meeting of the Board of Directors
April
Apr 13th 2011Orion upgrades full-year outlook for 2011
Apr 18th 2011Orion invites analysts and media to Q1 news conference on Wednesday 27 April 2011
Apr 20th 2011397,408 Orion A-shares converted into B-shares
Apr 27th 2011Orion Group Interim Report January-March 2011
May
May 5th 2011173,500 Orion A-shares converted into B-shares
June
Jun 9th 2011628,914 Orion A-shares converted into B-shares
Jun 22nd 2011100,000 Orion A-shares converted into B-shares
July
Jul 18th 2011Orion invites analysts and media to Q2 news conference on Tuesday 2 August 2011
Jul 22nd 2011Orion receives positive CHMP opinion for new intensive care sedative, dexdor® (dexmedetomidine)
August
Aug 2nd 2011Orion Corporation's publication schedules for financial reporting in 2012
Aug 2nd 2011Orion Group Interim Report January-June 2011
Aug 19th 2011136,231 Orion A-shares converted into B-shares
September
Sep 14th 2011400,000 Orion A-shares converted into B-shares
Sep 21st 2011Orion receives European marketing authorisation for dexdor®
Sep 21st 2011Composition of the Nomination Committee of Orion Corporation
Sep 23rd 2011400,000 Orion A-shares converted into B-shares
Sep 26th 2011Disclosure Under Chapter 2 Section 10
October
Oct 11th 2011Orion invites analysts and media to Q3 news conference on Tuesday 25 October 2011
Oct 25th 2011Orion Group Interim Report January-September 2011
Oct 25th 2011Change in Orion Group Executive Management Board as of 1 January 2012
November
Nov 7th 201153,428 Orion A-shares converted into B-shares
Nov 7th 2011Disclosure Under Chapter 2 Section 10
December
Dec 20th 2011Orion Corporation: 201,000 Orion A-shares converted into B-shares

Orion Corporation

Timo Lappalainen
President and CEO

Olli Huotari
SVP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.